Poly-COV01

Poly-COV01 is an investigational **niclosamide-based injectable formulation** being developed by CNPharm and Hyundai Bioscience for the treatment of **severe COVID-19**. Public descriptions indicate that it was designed using a proprietary drug-delivery platform to overcome niclosamide's short systemic half-life and poor pharmacokinetic suitability for severe systemic infection, with the goal of maintaining blood concentrations above the reported antiviral **IC100** for prolonged periods after administration. Based on available public information, Poly-COV01 appears to be a **reformulated pharmaceutical product** rather than a new active ingredient, and its intended mechanism is best understood as systemic delivery of niclosamide for antiviral activity against **SARS-CoV-2**; however, the precise validated human mechanism, formulation composition, and clinical development details remain incompletely disclosed in primary sources.